BioAge Labs, Inc.
corporate_fare Company Profile
BioAge Labs, Inc. (NASDAQ:BIOA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for BIOA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for BIOA spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- BioAge 10-Q: Q3 Net Loss Widens to $33.5M as BGE-102 Costs Climb; $352.3M Cash Funds Runway Through 2029
- BioAge Posts Wider Q3 Loss as BGE-102 Trials Advance; QUELL-CV Data Due Q4
- BioAge Doses First Patient in Phase 2 DME Trial for Oral NLRP3 Inhibitor
- BioAge Labs Q2 2026: $381M Cash, BGE-102 Phase 2 Underway, Insiders Adopt 10b5-1 Plans
- BioAge Labs Q2 2026: $381M Cash Funds Pipeline Through 2029, Phase 2 Data in H2 2026
Financial Snapshot
Short Interest & Short Volume
4.34 days to coverFINRA reported short interest of 3,725,017 shares in BIOA as of the October 30, 2026 settlement, a 8.6% increase from the prior period — about 4.3 days to cover at its recent average daily volume. On November 20, 2026, 57.7% of BIOA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.